Chip Clonal Hematopoiesis Agent

<!--

BioTender-max Updated Sep 17, 2026

Install

Press C to copy

$ npx skillmds@latest add biotender-max/chip-clonal-hematopoiesis-agent

Installs into ~/.claude/skills (or .claude/skills inside a project). Restart Claude Code to pick it up.

Download SKILL.md

＋ Add to plugin

README badge

[![SkillMD](https://skillmd.com/badge/biotender-max/chip-clonal-hematopoiesis-agent.svg)](https://skillmd.com/skills/biotender-max/chip-clonal-hematopoiesis-agent)

Trust & safety

Audits pending

Not yet audited · commit a85fcac

Works with: Claude Code Claude.ai OpenAI Codex +

File contents

name: 'chip-clonal-hematopoiesis-agent' description: 'AI-powered clonal hematopoiesis of indeterminate potential (CHIP) detection, risk stratification, and cardiovascular/malignancy risk prediction using genomic and clinical data.' measurable_outcome: Execute skill workflow successfully with valid output within 15 minutes. allowed-tools: - read_file - run_shell_command

CHIP Clonal Hematopoiesis Agent

The CHIP Clonal Hematopoiesis Agent provides comprehensive detection and risk stratification of clonal hematopoiesis of indeterminate potential (CHIP). It identifies clonal mutations in blood cells, assesses risk of progression to myeloid malignancy, and predicts cardiovascular disease risk, integrating with the CHIC machine learning framework for CBC-based screening.

When to Use This Skill

When detecting CHIP mutations from blood sequencing data.
For stratifying risk of progression to MDS/AML.
To assess CHIP-associated cardiovascular disease risk.
When filtering CHIP variants from tumor liquid biopsy.
For population-level CHIP screening and research.

Core Capabilities

CHIP Detection: Identify clonal mutations with VAF >2%.
Risk Stratification: Predict myeloid malignancy progression risk.
CVD Risk Assessment: Estimate cardiovascular disease risk.
CCUS Classification: Distinguish CHIP from CCUS/MDS.
Clone Size Tracking: Monitor clonal evolution over time.
ctDNA Filtering: Remove CHIP from tumor ctDNA analysis.

CHIP-Associated Genes

Gene	Frequency	Malignancy Risk	CVD Risk
DNMT3A	50%	Moderate	Elevated
TET2	20%	Moderate	Elevated (inflammatory)
ASXL1	10%	High	Moderate
JAK2	5%	High (MPN)	Elevated (thrombosis)
TP53	5%	Very High	Low
SF3B1	3%	Moderate-High	Low
SRSF2	3%	High	Low
PPM1D	2%	Moderate	Therapy-related
CBL	2%	High	Moderate
IDH1/2	2%	Moderate-High	Low

Risk Categories

Category	Criteria	Annual AML Risk
Low-Risk CHIP	DNMT3A/TET2, VAF <10%	<0.5%
Intermediate CHIP	DNMT3A/TET2, VAF >10%	0.5-1%
High-Risk CHIP	ASXL1, TP53, splicing	1-3%
CCUS	CHIP + cytopenia	3-10%
Pre-MDS	High-risk mutations + dysplasia	>10%

Workflow

Input: Blood sequencing (WES/panel), CBC data, clinical history.
Variant Detection: Call somatic variants with VAF filtering.
CHIP Classification: Identify CHIP-defining mutations.
Risk Scoring: Calculate malignancy and CVD risk scores.
Longitudinal Analysis: Track clone dynamics if serial samples.
Clinical Integration: Generate management recommendations.
Output: CHIP status, risk scores, monitoring plan.

Example Usage

User: "Analyze this patient's blood sequencing for CHIP and calculate their risk of progression and cardiovascular events."

Agent Action:

python3 Skills/Hematology/CHIP_Clonal_Hematopoiesis_Agent/chip_analysis.py \
    --variants blood_variants.vcf \
    --cbc_data patient_cbc.csv \
    --clinical_data patient_demographics.json \
    --vaf_threshold 0.02 \
    --age 65 \
    --calculate_cvd_risk true \
    --output chip_analysis/

CHRS Risk Score (Clonal Hematopoiesis Risk Score)

Factor	Points	Notes
High-risk mutation	+2	SRSF2, SF3B1, ZRSR2, IDH1/2, FLT3, RUNX1, JAK2
Single DNMT3A mutation	-1	Lower risk
≥2 mutations	+1	Increased burden
VAF ≥20%	+1	Large clone
CCUS (vs CHIP)	+2	Cytopenia present
RDW ≥15%	+1	Blood count abnormality
MCV ≥100 fL	+1	Macrocytosis
Age ≥65	+1	Age-related risk

Output Components

Output	Description	Format
CHIP Status	Present/Absent, genes involved	.json
Mutation Details	VAF, gene, protein change	.csv
Malignancy Risk	5-year AML/MDS probability	.json
CVD Risk	Cardiovascular risk score	.json
CHRS Score	Clonal hematopoiesis risk score	.json
Recommendations	Clinical management	.md
Monitoring Plan	Follow-up schedule	.json

AI/ML Components

CHIC Framework:

Machine learning from CBC indices
Identifies high-risk CHIP without sequencing
Reduces "number needed to sequence"

Risk Prediction:

Cox proportional hazards for progression
Random survival forests
Deep learning survival models

CVD Risk Integration:

Framingham score adjustment
CHIP-specific hazard ratios
Inflammatory biomarker integration

Cardiovascular Risk

CHIP Gene	CVD Hazard Ratio	Mechanism
TET2	1.9	IL-6, inflammasome
DNMT3A	1.7	Inflammation
JAK2	2.6	Thrombosis, platelet activation
ASXL1	2.0	Inflammation
Overall CHIP	1.5-2.0	Multiple pathways

Clinical Management Guidelines

CHIP Category	Monitoring	Intervention
Low-risk	Annual CBC	None
Intermediate	CBC q6 months	CVD optimization
High-risk	CBC q3-6 months, consider BMB	Hematology referral
CCUS	BMB, q3 month CBC	Active surveillance

Prerequisites

Python 3.10+
Variant callers (Mutect2, VarScan)
ANNOVAR/VEP for annotation
lifelines, scikit-survival
CHIC model weights

Related Skills

MPN_Progression_Monitor_Agent - MPN monitoring
CHIC_ML_Framework_Agent - CBC-based screening
MDS_Classification_Agent - MDS diagnosis
Bone_Marrow_AI_Agent - Morphology analysis

CHIP vs ctDNA Filtering

Feature	CHIP	Tumor ctDNA
VAF Stability	Stable over time	Changes with disease
Genes	DNMT3A, TET2, ASXL1	Tumor drivers
Age Association	Increases with age	Independent
Multiple Samples	Consistent	Variable

Special Considerations

VAF Threshold: Use 2% for CHIP definition
Germline Filtering: Exclude germline variants
Age Context: Prevalence increases with age
Therapy History: Consider treatment-related clones
Serial Monitoring: Track clone dynamics

Population Prevalence

Age Group	CHIP Prevalence	High-Risk CHIP
40-49	~2%	<0.5%
50-59	~5%	~1%
60-69	~10%	~2%
70-79	~15%	~4%
80+	~20%	~5%

Therapeutic Implications

Scenario	CHIP Impact	Consideration
CAR-T Therapy	May affect outcomes	Monitor clones
Stem Cell Transplant	Donor CHIP matters	Screen donors
Chemotherapy	May expand clones	Monitor post-treatment
Cardiovascular	Increased risk	Aggressive prevention

Author

AI Group - Biomedical AI Platform

---name: chip-clonal-hematopoiesis-agentdescription: ---name: 'chip-clonal-hematopoiesis-agent'description: 'AI-powered clonal hematopoiesis of indeterminate potential (CHIP) detection, risk stratification, and cardiovascular/malignancy risk prediction using genomic and clinical data.'measurable_outcome: Execute skill workflow successfully with valid output within 15 minutes.allowed-tools: - read_file - run_shell_command---# CHIP Clonal Hematopoiesis AgentThe **CHIP Clonal Hematopoiesis Agent** provides comprehensive detection and risk stratification of clonal hematopoiesis of indeterminate potential (CHIP). It identifies clonal mutations in blood cells, assesses risk of progression to myeloid malignancy, and predicts cardiovascular disease risk, integrating with the CHIC machine learning framework for CBC-based screening.## When to Use This Skill* When detecting CHIP mutations from blood sequencing data.* For stratifying risk of progression to MDS/AML.* To assess CHIP-associated cardiovascular disease risk.* When filtering CHIP variants from tumor liquid biopsy.* For population-level CHIP screening and research.## Core Capabilities1. **CHIP Detection**: Identify clonal mutations with VAF >2%.2. **Risk Stratification**: Predict myeloid malignancy progression risk.3. **CVD Risk Assessment**: Estimate cardiovascular disease risk.4. **CCUS Classification**: Distinguish CHIP from CCUS/MDS.5. **Clone Size Tracking**: Monitor clonal evolution over time.6. **ctDNA Filtering**: Remove CHIP from tumor ctDNA analysis.## CHIP-Associated Genes| Gene | Frequency | Malignancy Risk | CVD Risk ||------|-----------|-----------------|----------|| DNMT3A | 50% | Moderate | Elevated || TET2 | 20% | Moderate | Elevated (inflammatory) || ASXL1 | 10% | High | Moderate || JAK2 | 5% | High (MPN) | Elevated (thrombosis) || TP53 | 5% | Very High | Low || SF3B1 | 3% | Moderate-High | Low || SRSF2 | 3% | High | Low || PPM1D | 2% | Moderate | Therapy-related || CBL | 2% | High | Moderate || IDH1/2 | 2% | Moderate-High | Low |## Risk Categories| Category | Criteria | Annual AML Risk ||----------|----------|-----------------|| Low-Risk CHIP | DNMT3A/TET2, VAF <10% | <0.5% || Intermediate CHIP | DNMT3A/TET2, VAF >10% | 0.5-1% || High-Risk CHIP | ASXL1, TP53, splicing | 1-3% || CCUS | CHIP + cytopenia | 3-10% || Pre-MDS | High-risk mutations + dysplasia | >10% |## Workflow1. **Input**: Blood sequencing (WES/panel), CBC data, clinical history.2. **Variant Detection**: Call somatic variants with VAF filtering.3. **CHIP Classification**: Identify CHIP-defining mutations.4. **Risk Scoring**: Calculate malignancy and CVD risk scores.5. **Longitudinal Analysis**: Track clone dynamics if serial samples.6. **Clinical Integration**: Generate management recommendations.7. **Output**: CHIP status, risk scores, monitoring plan.## Example Usage**User**: "Analyze this patient's blood sequencing for CHIP and calculate their risk of progression and cardiovascular events."**Agent Action**:```bashpython3 Skills/Hematology/CHIP_Clonal_Hematopoiesis_Agent/chip_analysis.py \ --variants blood_variants.vcf \ --cbc_data patient_cbc.csv \ --clinical_data patient_demographics.json \ --vaf_threshold 0.02 \ --age 65 \ --calculate_cvd_risk true \ --output chip_analysis/```## CHRS Risk Score (Clonal Hematopoiesis Risk Score)| Factor | Points | Notes ||--------|--------|-------|| High-risk mutation | +2 | SRSF2, SF3B1, ZRSR2, IDH1/2, FLT3, RUNX1, JAK2 || Single DNMT3A mutation | -1 | Lower risk || ≥2 mutations | +1 | Increased burden || VAF ≥20% | +1 | Large clone || CCUS (vs CHIP) | +2 | Cytopenia present || RDW ≥15% | +1 | Blood count abnormality || MCV ≥100 fL | +1 | Macrocytosis || Age ≥65 | +1 | Age-related risk |## Output Components| Output | Description | Format ||--------|-------------|--------|| CHIP Status | Present/Absent, genes involved | .json || Mutation Details | VAF, gene, protein change | .csv || Malignancy Risk | 5-year AML/MDS probability | .json || CVD Risk | Cardiovascular risk score | .json || CHRS Score | Clonal hematopoiesis risk score | .json || Recommendations | Clinical management | .md || Monitoring Plan | Follow-up schedule | .json |## AI/ML Components**CHIC Framework**:- Machine learning from CBC indices- Identifies high-risk CHIP without sequencing- Reduces "number needed to sequence"**Risk Prediction**:- Cox proportional hazards for progression- Random survival forests- Deep learning survival models**CVD Risk Integration**:- Framingham score adjustment- CHIP-specific hazard ratios- Inflammatory biomarker integration## Cardiovascular Risk| CHIP Gene | CVD Hazard Ratio | Mechanism ||-----------|------------------|-----------|| TET2 | 1.9 | IL-6, inflammasome || DNMT3A | 1.7 | Inflammation || JAK2 | 2.6 | Thrombosis, platelet activation || ASXL1 | 2.0 | Inflammation || Overall CHIP | 1.5-2.0 | Multiple pathways |## Clinical Management Guidelines| CHIP Category | Monitoring | Intervention ||---------------|------------|--------------|| Low-risk | Annual CBC | None || Intermediate | CBC q6 months | CVD optimization || High-risk | CBC q3-6 months, consider BMB | Hematology referral || CCUS | BMB, q3 month CBC | Active surveillance |## Prerequisites* Python 3.10+* Variant callers (Mutect2, VarScan)* ANNOVAR/VEP for annotation* lifelines, scikit-survival* CHIC model weights## Related Skills* MPN_Progression_Monitor_Agent - MPN monitoring* CHIC_ML_Framework_Agent - CBC-based screening* MDS_Classification_Agent - MDS diagnosis* Bone_Marrow_AI_Agent - Morphology analysis## CHIP vs ctDNA Filtering| Feature | CHIP | Tumor ctDNA ||---------|------|-------------|| VAF Stability | Stable over time | Changes with disease || Genes | DNMT3A, TET2, ASXL1 | Tumor drivers || Age Association | Increases with age | Independent || Multiple Samples | Consistent | Variable |## Special Considerations1. **VAF Threshold**: Use 2% for CHIP definition2. **Germline Filtering**: Exclude germline variants3. **Age Context**: Prevalence increases with age4. **Therapy History**: Consider treatment-related clones5. **Serial Monitoring**: Track clone dynamics## Population Prevalence| Age Group | CHIP Prevalence | High-Risk CHIP ||-----------|-----------------|----------------|| 40-49 | ~2% | <0.5% || 50-59 | ~5% | ~1% || 60-69 | ~10% | ~2% || 70-79 | ~15% | ~4% || 80+ | ~20% | ~5% |## Therapeutic Implications| Scenario | CHIP Impact | Consideration ||----------|-------------|---------------|| CAR-T Therapy | May affect outcomes | Monitor clones || Stem Cell Transplant | Donor CHIP matters | Screen donors || Chemotherapy | May expand clones | Monitor post-treatment || Cardiovascular | Increased risk | Aggressive prevention |## AuthorAI Group - Biomedical AI Platform

BioTender-max/awesome-bio-agent-skills/tree/main/skills/openclaw/chip-clonal-hematopoiesis-agent commit a85fcac2ab

Frequently asked questions

npx skillmds@latest add biotender-max/chip-clonal-hematopoiesis-agent